ArticleOncotarget2016

DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.

Wolfgang Gruber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.